Advertisement

Rheumatology International

, Volume 38, Issue 8, pp 1449–1454 | Cite as

Anti-cytokine therapy and plasma DNA in patients with rheumatoid arthritis

  • Lucia Lauková
  • Barbora Konečná
  • Barbora Vlková
  • Vanda Mlynáriková
  • Peter Celec
  • Emőke Šteňová
Biomarkers

Abstract

Background

Extracellular DNA (ecDNA) is increased in inflammation and it also induces inflammation. In patients with rheumatoid arthritis (RA), plasma ecDNA is higher than in healthy controls. Due to low specificity, it cannot be used for screening, but it might be useful for monitoring and prognosis of therapy success. The effect of treatment with biological disease-modifying antirheumatic drugs (bDMARDs) on plasma ecDNA in RA patients with regards to its subcellular origin has not been analyzed yet. The aim of this study was to describe the effects of bDMARDs on plasma ecDNA and its nuclear (nDNA) and mitochondrial (mtDNA) fractions in patients with RA.

Methods

Plasma samples of 32 patients with RA were collected before, as well as 3 and 6 months after starting the treatment with bDMARDs. Total plasma ecDNA was quantified fluorometrically. The subcellular origin of ecDNA was assessed using real time PCR. Treatment success was monitored using DAS28 and C-reactive protein (CRP).

Results

The clinical status of patients improved. Both DAS28 and CRP decreased by 52 and 73% after 3 months of treatment. Plasma ecDNA decreased significantly only after 6 months (by 26%). Real-time PCR showed that both, nDNA and mtDNA decreased by 63 and by 45% after 6 months.

Conclusion

Treatment with bDMARDs decreases plasma ecDNA of both nuclear and mitochondrial origin. Dynamics of ecDNA is slower than dynamics of standard clinical markers. Therefore, it is likely to be not useful for monitoring of the disease progress, at least for RA.

Keywords

Cell-free DNA DAMPs Innate immunity Biological therapy Immunosuppressive treatment 

Notes

Acknowledgements

This study was supported by the Ministry of Education of the Slovak Republic (VEGA 1/0156/17, VEGA 1/0092/17 and APVV-16-0273).

Author contributions

PC, BV, EŠ and VM designed and directed the study; LL, BV, and BK isolated and quantified DNA from plasma samples; LL analyzed the data; PC and LL wrote the article.

Funding

This study was funded by the Ministry of Education of the Slovak Republic (VEGA 1/0156/17).

Compliance with ethical standards

Conflict of interest

Lucia Lauková declares that there is no conflict of interest regarding the publication of this article. Barbora Konečná declares that there is no conflict of interest regarding the publication of this article. Barbora Vlková declares that there is no conflict of interest regarding the publication of this article. Vanda Mlynáriková declares that there is no conflict of interest regarding the publication of this article. Peter Celec declares that there is no conflict of interest regarding the publication of this article. Emőke Šteňová declares that there is no conflict of interest regarding the publication of this article.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Number of ethical approval: ICH GCP 135/95, date: 13.06.2016. Name of approving institution: Ethics Committee of University Hospital and Faculty of Medicine in Bratislava.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Zhong X-Y, von Mühlenen I, Li Y et al (2007) Increased concentrations of antibody-bound circulatory cell-free DNA in rheumatoid arthritis. Clin Chem 53:1609–1614.  https://doi.org/10.1373/clinchem.2006.084509 CrossRefPubMedGoogle Scholar
  2. 2.
    Dwivedi DJ, Toltl LJ, Swystun LL et al (2012) Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Crit Care 16:R151.  https://doi.org/10.1186/cc11466 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kostjuk S, Loseva P, Chvartatskaya O et al (2012) Extracellular GC-rich DNA activates TLR9- and NF-kB-dependent signaling pathways in human adipose-derived mesenchymal stem cells (haMSCs). Expert Opin Biol Ther 12:S99–S111.  https://doi.org/10.1517/14712598.2012.690028 CrossRefPubMedGoogle Scholar
  4. 4.
    Miyake K, Onji M (2013) Endocytosis-free DNA sensing by cell surface TLR9 in neutrophils: Rapid defense with autoimmune risks. Eur J Immunol 43:2006–2009.  https://doi.org/10.1002/eji.201343882 CrossRefPubMedGoogle Scholar
  5. 5.
    Sur Chowdhury C, Giaglis S, Walker UA et al (2014) Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther 16:R122.  https://doi.org/10.1186/ar4579 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Singh JA, Hossain A, Tanjong Ghogomu E et al (2016) Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev 13:CD012183.  https://doi.org/10.1002/14651858.CD012183 CrossRefGoogle Scholar
  7. 7.
    Hashimoto T, Yoshida K, Hashimoto N et al (2017) Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis. Int J Rheum Dis 20:722–730.  https://doi.org/10.1111/1756-185X.12959 CrossRefPubMedGoogle Scholar
  8. 8.
    Fransen J, van Riel PLCM. (2009) The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 35:745–757.  https://doi.org/10.1016/j.rdc.2009.10.001 CrossRefPubMedGoogle Scholar
  9. 9.
    Tsuji N, Tsuji T, Ohashi N et al (2016) Role of mitochondrial DNA in septic AKI via toll-Like receptor 9. J Am Soc Nephrol 27:2009–2020.  https://doi.org/10.1681/ASN.2015040376 CrossRefPubMedGoogle Scholar
  10. 10.
    Rykova E, Sizikov A, Roggenbuck D et al (2017) Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers. Arthritis Res Ther 19:85.  https://doi.org/10.1186/s13075-017-1295-z CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Pratesi F, Dioni I, Tommasi C et al (2014) Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. Ann Rheum Dis 73:1414–1422.  https://doi.org/10.1136/annrheumdis-2012-202765 CrossRefPubMedGoogle Scholar
  12. 12.
    Szekanecz Z, Soós L, Szabó Z et al (2008) Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets? Clin Rev Allergy Immunol 34:26–31.  https://doi.org/10.1007/s12016-007-8022-5 CrossRefPubMedGoogle Scholar
  13. 13.
    Dunaeva M, Buddingh’ BC, Toes REM et al (2015) Decreased serum cell-free DNA levels in rheumatoid arthritis. Auto Immun Highlights 6:23–30.  https://doi.org/10.1007/s13317-015-0066-6 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Sun K, Jiang P, Chan KCA et al (2015) Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci 112:E5503–E5512.  https://doi.org/10.1073/pnas.1508736112 CrossRefPubMedGoogle Scholar
  15. 15.
    Jiménez-Alcázar M, Napirei M, Panda R et al (2015) Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. J Thromb Haemost 13:732–742.  https://doi.org/10.1111/jth.12796 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute of Molecular Biomedicine, Faculty of MedicineComenius UniversityBratislavaSlovakia
  2. 2.National Institute of Rheumatic DiseasesPiešťanySlovakia
  3. 3.Institute of Pathophysiology, Faculty of MedicineComenius UniversityBratislavaSlovakia
  4. 4.Department of Molecular Biology, Faculty of Natural SciencesComenius UniversityBratislavaSlovakia
  5. 5.1st Department of Internal Medicine, Faculty of Medicine, University HospitalComenius UniversityBratislavaSlovakia

Personalised recommendations